Virax Biolabs (VRAX) Retained Earnings (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Retained Earnings of -$29.6 million for Q1 2026, down 20.43% year-over-year from -$37.2 million in Q1 2025, and down 20.43% quarter-over-quarter from -$24.6 million in Q1 2025.
Virax Biolabs (VRAX) Retained Earnings (2021 - 2026) Analysis & Trends
Virax Biolabs' Retained Earnings history runs 6 years deep, the most recent figure standing at -$29.6 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 20.43% year-over-year to -$29.6 million; the TTM figure through Mar 2026 stood at -$29.6 million (down 20.43% YoY), while the FY2026 annual figure was -$29.6 million, down 20.43% from the prior year.
- Retained Earnings for Q1 2026 stood at -$29.6 million, down from -$24.6 million in the prior quarter.
- The five-year high for Retained Earnings was -$6.3 million in Q1 2022, with the low at -$29.6 million in Q1 2026.
- The 5-year median for Retained Earnings is -$18.5 million (2024), against an average of -$18.2 million.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings sank 229167.95% in 2022, then declined 20.43% in 2026.
- Virax Biolabs' Retained Earnings stood at -$6.3 million in 2022, then plunged by 86.12% to -$11.8 million in 2023, then tumbled by 57.09% to -$18.5 million in 2024, then tumbled by 32.71% to -$24.6 million in 2025, then retreated by 20.43% to -$29.6 million in 2026.
- Business Quant data shows VRAX's Retained Earnings at -$29.6 million in Q1 2026, -$24.6 million in Q1 2025, and -$18.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 4.38 Bn |
| 10 | Virax Biolabs | 1.30 Mn | -5.14 Mn | - | -29.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.61 Mn |
| Mar 31, 2025 | -24.59 Mn |
| Mar 31, 2024 | -18.53 Mn |
| Mar 31, 2023 | -11.79 Mn |
| Mar 31, 2022 | -6.34 Mn |
| Mar 31, 2021 | -2,764.00 |